Plant Name: Corydalis ternata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ADORA3; ADORA2A; ADORA1; HTR7; HTR5A; ADRA1A; ADRA2C; ADRA2B; CHRM1; DRD1; DRD2; DRD3; HTR2B; HTR2A; HTR1A; HTR6; | |
| GAA; BCHE; ACHE; | |
| TDP1; MTOR; ADK; PKM; HPGD; ALOX15; | |
| HIF1A; TP53; NFKB1; STAT6; | |
| CREBBP; | |
| SLC28A2; SLC28A1; SLC28A3; | |
| HTT; LMNA; RAD52; F3; MAPT; THPO; SIGMAR1; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | CREBBP | CREB-binding protein | Q92793 | CHEMBL5747 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | ADRA1A | Alpha-1a adrenergic receptor | P35348 | CHEMBL229 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAD52 | DNA repair protein RAD52 homolog | P43351 | CHEMBL2362978 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 2.286E-12 | 3.112E-09 | ADORA1, ADORA2A, ADORA3, ADRA1A, ADRA2B, ADRA2C, CHRM1, DRD1, DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SIGMAR1, SLC28A1, SLC28A2, SLC28A3, TSHR |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 2.792E-12 | 3.116E-09 | ADORA1, ADORA2A, ADORA3, ADRA1A, ADRA2B, ADRA2C, CHRM1, DRD1, DRD2, DRD3, F3, HPGD, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SIGMAR1, TSHR |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.940E-11 | 1.457E-08 | HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.940E-11 | 1.457E-08 | HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 3.130E-11 | 2.130E-08 | HTR1A, HTR2A, HTR2B, HTR5A, HTR7 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.364E-10 | 8.251E-08 | ADORA1, ADORA2A, ADORA3, ADRA1A, ADRA2B, ADRA2C, CHRM1, DRD1, DRD2, DRD3, F3, HPGD, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SIGMAR1, TSHR |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.598E-10 | 2.275E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 2.164E-08 | 7.034E-06 | ADORA2A, DRD1, DRD2, DRD3 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 3.465E-08 | 1.048E-05 | ADORA1, ADORA2A, DRD1, DRD2, DRD3, HTR2A, HTR2B, HTT |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 5.391E-08 | 1.381E-05 | HTR1A, HTR5A, HTR7 |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 1.085E-07 | 2.486E-05 | DRD1, DRD2, DRD3, HIF1A, MTOR |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 1.448E-07 | 3.123E-05 | DRD1, DRD2, DRD3, HTR2A |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 1.448E-07 | 3.123E-05 | ADRA1A, ADRA2B, ADRA2C, DRD2 |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 4.422E-07 | 8.229E-05 | ADORA2A, DRD1, DRD2, DRD3 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 4.693E-07 | 8.242E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 7.497E-07 | 1.200E-04 | DRD1, DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 7.397E-07 | 1.200E-04 | ACHE, ADORA2A, ADRA2C, BCHE, DRD2, HPGD, HTT, MAPT, MTOR, NFKB1, PKM, RAD52, SMN1, SMN2, STAT6, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0001659; temperature homeostasis | 9.224E-07 | 1.445E-04 | ADORA1, DRD1, DRD2, HTR2A |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.123E-06 | 1.674E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.811E-06 | 2.512E-04 | ADORA1, ADORA2A, DRD1, DRD2, DRD3, HIF1A, HTR2A, HTR2B, HTT |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 2.197E-06 | 2.972E-04 | DRD2, DRD3, HTR2B |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.925E-06 | 3.837E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.925E-06 | 3.837E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:0035815; positive regulation of renal sodium excretion | 3.796E-06 | 4.644E-04 | ADORA2A, DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 3.796E-06 | 4.644E-04 | DRD1, DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.260E-06 | 5.097E-04 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 4.823E-06 | 5.646E-04 | ADORA1, DRD2, HTR2A |
| BP | GO:0007610; behavior | GO:0007613; memory | 5.517E-06 | 6.224E-04 | DRD1, DRD2, HTR2A, MAPT, MTOR |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 5.795E-06 | 6.405E-04 | SLC28A2, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 5.795E-06 | 6.405E-04 | ACHE, BCHE |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 5.795E-06 | 6.405E-04 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 5.795E-06 | 6.405E-04 | SLC28A2, SLC28A3 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 7.395E-06 | 7.971E-04 | ADORA1, ADORA2A, MAPT |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 7.906E-06 | 8.357E-04 | ADRA1A, ALOX15, DRD2, HTR2A, HTR2B, THPO |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 8.251E-06 | 8.564E-04 | BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| CC | GO:0044464; cell part | GO:0030425; dendrite | 1.507E-05 | 1.408E-03 | ADORA2A, CHRM1, DRD2, HTR5A, HTT, MAPT, MTOR |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.727E-05 | 1.512E-03 | ADORA2A, DRD1, DRD2, DRD3, HIF1A, HTT |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.736E-05 | 1.512E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.736E-05 | 1.512E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 1.736E-05 | 1.512E-03 | DRD2, DRD3 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.736E-05 | 1.512E-03 | SLC28A1, SLC28A3 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.736E-05 | 1.512E-03 | ADRA2B, ADRA2C |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.736E-05 | 1.512E-03 | ADORA1, ADORA2A |
| BP | GO:0051179; localization | GO:0043270; positive regulation of ion transport | 2.312E-05 | 1.916E-03 | ADORA1, ADORA2A, CHRM1, DRD1, DRD2, HTT |
| BP | GO:0051179; localization | GO:0043271; negative regulation of ion transport | 2.314E-05 | 1.916E-03 | ADORA1, DRD2, DRD3, HTR2A, MTOR |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.311E-05 | 1.916E-03 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 2.362E-05 | 1.941E-03 | ADORA1, ADORA2A, ADRA1A, ADRA2C, DRD2, HIF1A, NFKB1, TP53 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 2.508E-05 | 2.037E-03 | CREBBP, HIF1A, HTT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 2.560E-05 | 2.072E-03 | ADRA1A, BCHE, CYP1A2, HPGD, HTR5A, MTOR, NFKB1, PKM, TSHR |
| BP | GO:0065007; biological regulation | GO:0007202; activation of phospholipase C activity | 2.636E-05 | 2.118E-03 | ADRA1A, HTR2A, HTR2B |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 3.466E-05 | 2.662E-03 | ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 3.466E-05 | 2.662E-03 | ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.466E-05 | 2.662E-03 | CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 4.238E-05 | 3.131E-03 | DRD2, DRD3, HTR2A |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.242E-05 | 3.131E-03 | ALOX15, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008283; cell proliferation | GO:0001938; positive regulation of endothelial cell proliferation | 5.645E-05 | 3.925E-03 | F3, HIF1A, HTR2B, MTOR |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 5.768E-05 | 3.925E-03 | DRD1, DRD2 |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 5.768E-05 | 3.925E-03 | DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0042321; negative regulation of circadian sleep/wake cycle, sleep | 5.768E-05 | 3.925E-03 | ADORA1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 5.768E-05 | 3.925E-03 | HTR2A, HTR2B |
| BP | GO:0065007; biological regulation | GO:0045777; positive regulation of blood pressure | 5.785E-05 | 3.925E-03 | ADORA1, ADRA1A, ADRA2B |
| BP | GO:0050896; response to stimulus | GO:0043278; response to morphine | 6.373E-05 | 4.205E-03 | DRD2, DRD3, MTOR |
| BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 6.373E-05 | 4.205E-03 | GAA, HTR2B, MTOR |
| BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 6.998E-05 | 4.563E-03 | ADRA1A, ADRA2C, HTR2A |
| BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 7.232E-05 | 4.701E-03 | ADORA2A, DRD1, DRD2, DRD3, GAA |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 7.663E-05 | 4.879E-03 | ADRA2B, ADRA2C, MTOR |
| BP | GO:0032501; multicellular organismal process | GO:0051930; regulation of sensory perception of pain | 7.663E-05 | 4.879E-03 | ADORA1, ADRA2C, MTOR |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.663E-05 | 4.879E-03 | CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 8.638E-05 | 5.314E-03 | ALOX15, HPGD |
| BP | GO:0040011; locomotion | GO:0030334; regulation of cell migration | 8.812E-05 | 5.390E-03 | ADORA1, ADORA3, DRD1, DRD2, F3, HIF1A, LMNA, MTOR, TP53 |
| BP | GO:0051179; localization | GO:0043266; regulation of potassium ion transport | 9.399E-05 | 5.685E-03 | ADORA1, DRD1, DRD2, HTR2A |
| BP | GO:0065007; biological regulation | GO:0007190; activation of adenylate cyclase activity | 9.899E-05 | 5.938E-03 | ADORA3, DRD1, TSHR |
| CC | GO:0043226; organelle | GO:0014069; postsynaptic density | 1.163E-04 | 6.847E-03 | ADORA1, ADORA2A, CHRM1, DRD2, SIGMAR1 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.184E-04 | 6.948E-03 | HIF1A, LMNA, MTOR, TP53 |
| BP | GO:0023052; signaling | GO:0032222; regulation of synaptic transmission, cholinergic | 1.208E-04 | 7.030E-03 | ACHE, ADORA2A |
| MF | GO:0005488; binding | GO:0031072; heat shock protein binding | 1.228E-04 | 7.114E-03 | ADORA1, HIF1A, HTT, MAPT |
| BP | GO:0065007; biological regulation | GO:0045776; negative regulation of blood pressure | 1.450E-04 | 8.288E-03 | ADORA1, DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 1.499E-04 | 8.501E-03 | ADORA1, ADORA2A, CREBBP, DRD2, F3, HIF1A, LMNA, MAPT, MTOR, NFKB1, RAD52, TP53 |
| BP | GO:0009987; cellular process | GO:0051896; regulation of protein kinase B signaling | 1.567E-04 | 8.725E-03 | DRD2, DRD3, F3, MTOR, THPO |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 1.608E-04 | 8.862E-03 | ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.608E-04 | 8.862E-03 | ADRA2B, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 1.608E-04 | 8.862E-03 | DRD2, DRD3 |
| BP | GO:0008152; metabolic process | GO:0044281; small molecule metabolic process | 1.651E-04 | 9.076E-03 | ADK, ADORA2A, ALOX15, CYP1A2, CYP2C19, CYP2D6, CYP3A4, GAA, HIF1A, HPGD, HTR2B, MTOR, PKM |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 1.745E-04 | 9.525E-03 | DRD2, HTR5A, SMN1, SMN2 |
| BP | GO:0065007; biological regulation | GO:0045761; regulation of adenylate cyclase activity | 1.783E-04 | 9.659E-03 | DRD2, DRD3, TSHR |
| BP | GO:0051179; localization | GO:0051209; release of sequestered calcium ion into cytosol | 1.783E-04 | 9.659E-03 | DRD2, HTR2A, HTR2B |
| BP | GO:0008152; metabolic process | GO:0009152; purine ribonucleotide biosynthetic process | 1.804E-04 | 9.741E-03 | ADK, ADORA2A, HTR2B, PKM |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.930E-20 | 4.014E-18 | CHRM1; HTR1A; HTR2B; HTR2A; HTR5A; ADRA2C; ADRA2B; ADRA1A; TSHR; HTR6; HTR7; ADORA2A; ADORA3; ADORA1; DRD1; DRD2; DRD3 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.455E-12 | 3.052E-10 | HTR6; HTR7; CYP2D6; ALOX15; HTR1A; HTR2B; HTR2A; HTR5A; CYP2C19 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.851E-11 | 1.302E-09 | CREBBP; HTR6; CHRM1; ADORA2A; ADORA1; HTR1A; DRD1; DRD2; NFKB1; TSHR |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 3.218E-10 | 1.102E-08 | HTR6; CHRM1; HTR7; ADORA2A; HTR2B; HTR2A; DRD1; HTR5A; ADRA1A |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.089E-07 | 1.668E-05 | CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.841E-05 | 4.049E-04 | PKM; TP53; HIF1A; MTOR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.069E-05 | 4.049E-04 | CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 4.416E-05 | 7.563E-04 | ADORA3; ADORA1; ADRA2C; ADRA2B; ADRA1A |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.646E-05 | 7.735E-04 | CREBBP; TP53; NFKB1; MTOR |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 5.401E-05 | 7.735E-04 | HTR2B; HTR2A; DRD1; DRD2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 9.981E-05 | 1.243E-03 | CREBBP; HIF1A; NFKB1; MTOR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.688E-04 | 1.898E-03 | CREBBP; TP53; HIF1A; MTOR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.801E-04 | 1.898E-03 | ADORA3; ADORA1; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.809E-04 | 3.479E-03 | CREBBP; STAT6; TP53; NFKB1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 5.134E-04 | 4.396E-03 | CREBBP; THPO; STAT6; MTOR |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.077E-04 | 2.033E-03 | DRD1; DRD2; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.354E-03 | 9.614E-03 | CREBBP; PKM; TP53; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.324E-03 | 1.516E-02 | CREBBP; HIF1A; TP53; NFKB1; MTOR |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.741E-04 | 5.432E-03 | CYP2D6; CYP1A2; CYP3A4 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.404E-03 | 9.614E-03 | TP53; NFKB1; MTOR |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.457E-04 | 7.198E-03 | CYP1A2; CYP3A4; CYP2C19 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.346E-03 | 2.581E-02 | LMNA; TP53; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 3.456E-03 | 2.152E-02 | DRD1; DRD2; DRD3 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.147E-03 | 2.820E-02 | CREBBP; TP53; NFKB1; MTOR |
| hsa05012 | Parkinson's disease_Homo sapiens_hsa05012 | 4.522E-03 | 2.581E-02 | ADORA2A; DRD1; DRD2 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 8.320E-03 | 3.521E-02 | CHRM1; TP53; NFKB1; MTOR |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 8.565E-03 | 3.521E-02 | ADORA2A; DRD1; DRD2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 8.696E-03 | 3.521E-02 | HPGD; TP53; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 7.678E-03 | 3.521E-02 | ADORA1; TSHR |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 9.368E-03 | 3.521E-02 | CREBBP; TP53; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.946E-03 | 3.521E-02 | NFKB1; MTOR |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 1.051E-02 | 3.521E-02 | CREBBP; HTT; TP53 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 5.692E-03 | 2.999E-02 | PKM; MTOR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.188E-02 | 3.665E-02 | CREBBP; TP53; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.204E-02 | 3.665E-02 | TP53; HIF1A; MTOR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 8.773E-03 | 3.521E-02 | HIF1A; MTOR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.023E-02 | 3.521E-02 | TP53; MTOR |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 8.217E-03 | 3.521E-02 | CYP1A2; CYP3A4 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 9.345E-03 | 3.521E-02 | ALOX15; CYP2C19 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.023E-02 | 3.521E-02 | STAT6; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.054E-02 | 3.521E-02 | TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.023E-02 | 3.521E-02 | CYP1A2; CYP3A4 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.054E-02 | 3.521E-02 | CREBBP; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.278E-02 | 3.805E-02 | TP53; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.179E-02 | 3.665E-02 | NFKB1; MTOR |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.170E-02 | 3.665E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3; DRD1 |
| NA: NA | Corneal vascularity | NA | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1; HTR1A; ADRA2C; ADRA1A; DRD1; DRD2; DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; DRD2 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1 |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| NA: NA | Hyperaemia | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3 |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR1A; CYP3A4; DRD2; ACHE; HTR2A; HTR6; HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR1A; DRD1; HTR2A |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR1A; DRD3; DRD1; DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | CHRM1; CHRM1; ADORA2A; ADORA1; HTR1A; DRD1; DRD2; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; MTOR; HTR1A; ADK; ADRA2C; ADRA1A; DRD1; DRD2; ACHE; PKM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MTOR; F3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM1; ADORA1; HTR1A; ADRA1A; DRD1; ACHE; MAPT; HTR6 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM1; ADRA2C; HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; HTR1A |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MTOR; DRD2 |
| C00-D49: Neoplasms | Chronic myeloid leukemia | NA | CREBBP |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; ADRA2C |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2 |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; HTR2A |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; HTR2A |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B |
| NA: NA | Cervical dystonia | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; DRD2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ADRA1A |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | ADRA1A |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | ADRA1A |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; DRD3 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; HTR1A; HTR1A; ADRA1A; DRD2 |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; HTR6 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A |
| NA: NA | Episode | NA | HTR1A |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
| NA: NA | Excessive sweating | NA | CHRM1 |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR1A; HTR2B; HTR2A; CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CHRM1; ADORA2A; ADORA1; ADRA2B |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | CHRM1; ADORA2A; DRD2 |
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| NA: NA | Dystonia | NA | CHRM1 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MTOR; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT; HTR6 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; HTR1A; ADRA1A |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR1A; ADRA2C; HTR2B; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1; DRD1; HTR6 |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3 |
| NA: NA | Addiction | NA | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; DRD2; DRD2; DRD2 |
| N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1A; ADRA1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; DRD1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; DRD2 |
| NA: NA | Itching | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM1; HTR2B |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B |
| NA: NA | False perceptions | NA | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1 |
| NA: NA | Vomiting | NA | DRD2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; DRD2; HTR6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| NA: NA | Abdominal stomach pain | NA | CHRM1 |
| NA: NA | Functional bowel syndrome | NA | CHRM1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A; ADRA1A; DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Post-traumatic stress disorder | F43.1 | ADRA1A |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A |
| NA: NA | Coronary artery restenosis | NA | MTOR |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | DRD2; CYP2D6 |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1 |
| N00-N99: Diseases of the genitourinary system | Stress urinary incontinence | N39.3 | ADRA1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CHRM1; ADORA3; ADORA2A; ADORA1; ADRA2C; ADRA1A; DRD2; ACHE; HTR2A |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; ADRA2B; DRD2; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| NA: NA | Social phobia | NA | HTR1A |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRM1; HTR1A; HTR1A; ADRA2C; DRD2; ACHE; ACHE; ACHE; MAPT; HTR6; HTR6; HTR6 |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1A; HTR2A |
| NA: NA | Schizoaffective disorder | NA | HTR1A |
| NA: NA | Schizoaffective disorders | NA | CHRM1; DRD2 |
| NA: NA | Anxiety disorders | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MTOR; PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | MTOR; MTOR |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM1; CHRM1; HTR7; HTR1A; HTR1A; DRD3; DRD1; DRD2; DRD2; DRD2; DRD2; HTR2A; HTR2A; HTR6 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; CREBBP |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; HIF1A; TP53; MTOR; NFKB1; ACHE |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA2A; ADORA1; ADRA2C; DRD2 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| NA: NA | Bulimia nervosa | NA | HTR1A |